Real world outcomes of Mepolizumab for severe asthma in Wales a retrospective analysis.

A. Harries (Cardiff, United Kingdom), K. Pink (Cardiff, United Kingdom)

Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Session: Monoclonal antibodies in asthma
Session type: E-poster session
Number: 2214
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Harries (Cardiff, United Kingdom), K. Pink (Cardiff, United Kingdom). Real world outcomes of Mepolizumab for severe asthma in Wales a retrospective analysis.. 2214

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019


Omalizumab in severe allergic asthma: a 4-year real world experience, Fife, Scotland
Source: International Congress 2017 – Asthma management
Year: 2017


Analysis of clinical features of asthma exacerbations: a multicentre survey in Italy
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005

Real world evaluation of asthma control risk factors and management: findings from China national asthma control surveys
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017

Main cost drivers of costs for asthma in society - report from the obstructive lung disease in Northern Sweden studies (OLIN)
Source: Eur Respir J 2001; 18: Suppl. 33, 441s
Year: 2001

Efficacy of azithromycin in a real world severe asthma cohort
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021


Late Breaking Abstract - Real world patient-reported outcomes in asthma across six European countries: the NEWTON study
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021

Thunderstorm asthma in Melbourne, Australia: Single centre patient outcomes and clinical review
Source: International Congress 2017 – Many faces of asthma and allergies
Year: 2017


Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018


Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014

Predicting asthma exacerbations in children – A real life observational study
Source: International Congress 2015 – Highlights in paediatric epidemiology: air pollution, asthma and primary ciliary dyskinesia
Year: 2015

Late Breaking Abstract - Identifying preventable early risk factors for asthma in Indigenous children: a population cohort study in Western Australia.
Source: Virtual Congress 2020 – Diagnosis and management of asthma
Year: 2020




Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019



Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma.
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


Prevalence and incidence of type-1 allergy among school children in Northern Sweden - report from the obstructive lung disease in Northern Sweden studies (OLIN)
Source: Eur Respir J 2001; 18: Suppl. 33, 286s
Year: 2001

A national audit of severe life-threatening asthma in Singapore
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018

Incidence of asthma among school children in northern Sweden: a 2-year follow-up - report from the obstructive lung disease in northern Sweden studies (OLIN)
Source: Eur Respir J 2001; 18: Suppl. 33, 373s
Year: 2001

Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019


Healthcare utilization and cost associated with chronic cough in the United Kingdom: a retrospective observational study
Source: Virtual Congress 2020 – New and integrated tools for respiratory diagnosis and care
Year: 2020




The APEX study: A retrospective review of outcomes in patients with severe allergic asthma who were or were not hospitalised in the year prior to omalizumab initiation in UK clinical practice
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012